Amplifica Holdings Group, Inc., a US-based, privately held, clinical-stage biopharmaceutical company, announced on Thursday that it has entered into an exclusive license agreement with The Regents of the University of California for a proprietary pipeline product that expands upon research in hair biology.
Frank Fazio, president and CEO, said, 'Amplifica is focused on identifying and developing solutions for androgenic alopecia and this expanded agreement with the University of California is another example of the company's pursuit to combat hair loss.'
Development Cell, a peer-reviewed scientific journal of cell and developmental biology recently published early- stage results for SCUBE3, a multifunctional signalling protein. The data showcased that SCUBE3 helps growth of normal hair follicles and can potentially stimulate new hair growth when implemented to skin. SCUBE3 will now be referenced as AMP-601 and is presently undergoing pre-clinical testing at Amplifica.
Renew Biotechnologies names new chief operating officer
Teva, Sanofi accelerate inflammatory bowel disease drug trial
Ro adds David B Allison to Advisory Board
Charles River Laboratories and Autobahn Labs forge alliance to boost academic drug discovery
Nkarta partnering with Columbia on investigator-led lupus trial for NKX019
Gilead's lenacapavir demonstrates 100% efficacy in HIV prevention trial
Anixa Biosciences' ovarian cancer CAR-T therapy individual patient IND receives FDA approval
Evergreen Nephrology names new director
Emmaus Life Sciences names new chief executive officer
FDA feedback boosts Diamyd Medical's pathway to accelerated approval for Type 1 Diabetes Therapy
TC BioPharm (Holdings) doses sixth patient in TCB-008 clinical trial
Caidya names new chief executive officer
Ionis Pharmaceuticals reports positive results for ION582 in Angelman syndrome study
Nuvalent launches HEROEX-1 trial for HER2-selective inhibitor NVL-330
Astellas and Osaka University collaborate on stem cell therapy for disc degeneration